Technical Analysis for AMRN - Amarin Corporation plc
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
 |
17.93 | 0.34% | 0.06 |
AMRN closed up 0.34 percent on Friday, February 21, 2020, on 66 percent of normal volume. The price action carved out a bullish hammer (or hammer-like) candlestick pattern. That may indicate an upside reversal. Look for price to trade above the high of the hammer for confirmation.
Earnings due: Feb 25
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Flat |
| Historical AMRN trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Hammer Candlestick | Bullish | 0.00% | |
| Doji - Bullish? | Reversal | 0.00% | |
| MACD Bullish Signal Line Cross | Bullish | 0.34% | |
| 200 DMA Resistance | Bearish | -0.94% | |
| Narrow Range Bar | Range Contraction | 1.76% | |
| NR7 | Range Contraction | 1.76% | |
| Stochastic Reached Oversold | Weakness | 1.76% | |
| Oversold Stochastic | Weakness | 1.76% | |
| Oversold Stochastic | Weakness | 1.36% | |
| 200 DMA Resistance | Bearish | -1.38% |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 02/25/2020
- Sector: Healthcare
- Industry: Biotechnology
Amarin Corporation plc, a biopharmaceutical company, focuses on the development and commercialization therapeutic products for the treatment for cardiovascular diseases. Its product development program areas include lipid science and therapeutic benefits of polyunsaturated fatty acids. The company lead product comprises Vascepa, a prescription-only omega-3 fatty acid comprising icosapent ethyl as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. It also engages in developing Vascepa for the treatment of patients with high triglyceride levels who are also on statin therapy for elevated low-density lipoprotein cholesterol levels. The company was formerly known as Ethical Holdings plc. Amarin Corporation plc was founded in 1989 and is headquartered in Dublin, Ireland.
Biopharmaceutical Organic Compounds Nutrition Cardiovascular Diseases Cholesterol Low Density Lipoprotein Lipids Hypertriglyceridemia Saturated Fat
Biopharmaceutical Organic Compounds Nutrition Cardiovascular Diseases Cholesterol Low Density Lipoprotein Lipids Hypertriglyceridemia Saturated Fat
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 26.12 |
| 52 Week Low | 13.76 |
| Average Volume | 8,399,062 |
| 200-Day Moving Average | 18.34 |
| 50-Day Moving Average | 20.05 |
| 20-Day Moving Average | 18.53 |
| 10-Day Moving Average | 17.91 |
| Average True Range | 0.73 |
| ADX | 20.88 |
| +DI | 17.81 |
| -DI | 31.64 |
| Chandelier Exit (Long, 3 ATRs ) | 19.36 |
| Chandelier Exit (Short, 3 ATRs ) | 19.35 |
| Upper Bollinger Band | 20.10 |
| Lower Bollinger Band | 16.95 |
| Percent B (%b) | 0.31 |
| BandWidth | 17.01 |
| MACD Line | -0.60 |
| MACD Signal Line | -0.62 |
| MACD Histogram | 0.0255 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 18.86 | ||||
| Resistance 3 (R3) | 18.78 | 18.39 | 18.71 | ||
| Resistance 2 (R2) | 18.39 | 18.15 | 18.43 | 18.65 | |
| Resistance 1 (R1) | 18.16 | 18.01 | 18.28 | 18.24 | 18.60 |
| Pivot Point | 17.77 | 17.77 | 17.83 | 17.81 | 17.77 |
| Support 1 (S1) | 17.54 | 17.53 | 17.66 | 17.62 | 17.26 |
| Support 2 (S2) | 17.15 | 17.39 | 17.19 | 17.21 | |
| Support 3 (S3) | 16.92 | 17.15 | 17.16 | ||
| Support 4 (S4) | 17.00 |
